keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer pathology

keyword
https://www.readbyqxmd.com/read/30342294/advances-in-molecular-mechanisms-and-treatment-of-radiation-induced-pulmonary-fibrosis
#1
REVIEW
Zhongjie Chen, Zhiqiang Wu, Wen Ning
Radiation-induced pulmonary fibrosis (RIPF) is a common complication in patients with lung cancer and breast cancer after receiving thoracic radiotherapy. The average incidence of RIPF is 16%-28% after radiotherapy. RIPF includes a heterogeneous group of lung disorders characterized by progressive and irreversible destruction of lung architecture and disruption of gas exchange. The clinical signs of RIPF include increasing dyspnea, deteriorating lung function, and accumulation of interstitial fluid, eventually leading to respiratory failure...
October 17, 2018: Translational Oncology
https://www.readbyqxmd.com/read/30341462/prognosis-in-different-subtypes-of-metaplastic-breast-cancer-a-population-based-analysis
#2
Xuexin He, Jiali Ji, Rongrong Dong, Hong Liu, Xiaolan Dai, Chongjian Wang, Francisco J Esteva, Sai-Ching Jim Yeung
BACKGROUND: Metaplastic breast cancer (MpBC) is a rare histological subtype of breast cancer recognized as a unique pathologic entity in 2000. However, the pathogenesis, optimal therapy, and prognosis of MpBC and the potential effect of systemic treatments on different subtypes of MpBC are not well defined. METHODS: A retrospective population-based study was performed to identify breast cancer patients with MpBC and other triple-negative breast cancers (TNBC) between 2010 and 2014 using the surveillance, Epidemiology, and End Results (SEER) database...
October 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30340871/phase-ii-study-of-s-1-combined-with-low-dose-docetaxel-as-neoadjuvant-chemotherapy-for-operable-breast-cancer-patients-n-1-study
#3
Misako Nakagawa, Mayumi Ikeuchi, Masami Morimoto, Hirokazu Takechi, Hiroaki Toba, Takahiro Yoshida, Kazumasa Okumura, Naoki Hino, Aya Nishisho, Akira Tangoku
BACKGROUND: To improve the pathological complete response (pCR) rate, we devised new neoadjuvant chemotherapy. Efficacy and safety of the oral fluoropyrimidine derivative S-1 (Taiho Pharmaceutical Co, Tokyo, Japan) combined with low-dose docetaxel (S-1+DOC) were evaluated. PATIENTS AND METHODS: Patients were treated with docetaxel (40 mg/m2 intravenously on day 1) and S-1 (40 mg/m2 orally twice per day on days 1-14) every 3 weeks for 4 cycles. In accord with the Response Evaluation Criteria In Solid Tumors version 1...
September 27, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/30339245/identification-of-her2-immunohistochemistry-negative-fish-amplified-breast-cancers-and-their-response-to-anti-her2-neoadjuvant-chemotherapy
#4
I-Sanna Gibbons-Fideler, Hiroaki Nitta, Adrian Murillo, Gary Tozbikian, Peter Banks, Anil V Parwani, Zaibo Li
Objectives: Either immunohistochemistry (IHC) or in situ hybridization (ISH) can be used to determine human epidermal growth factor receptor 2 (HER2) status. Breast cancers (BCs) with HER2 IHC-negative (IHC-) and ISH-amplified (ISH+) results have been rarely reported but not well studied. We investigated the frequency of HER2 IHC-/ISH+ BCs and their response to anti-HER2 neoadjuvant chemotherapy (NAC). Methods: Seventeen BCs with HER2 IHC-/ISH+ results were identified from 1,107 consecutive invasive BCs (1...
October 18, 2018: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/30338792/the-role-of-fh-detection-combined-with-hpv-screening-on-the-diagnostic-significance-of-cervical-cancer-and-precancerous-lesions
#5
Y-J Hu, H-P Zhang, B Zhu, H-Y Chen, L-H Ma, Y Wang
OBJECTIVE: Cervical cancer is a common type in gynecologic malignant tumor that accounts for the leading morbidity only after breast cancer in female. This study aims to determine the diagnostic significance of uterine epithelial cells stability free body of iron protoporphyrin reduced state (FH) detection combined human papillomavirus (HPV) screening for cervical cancer. PATIENTS AND METHODS: A total of 800 patients were enrolled. FH test and HPV genotyping detection were performed...
October 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/30338678/tissue-oxygen-saturation-predicts-response-to-breast-cancer-neoadjuvant-chemotherapy-within-10-days-of-treatment
#6
Jeffrey M Cochran, David R Busch, Anaïs Leproux, Zheng Zhang, Thomas D O'Sullivan, Albert E Cerussi, Philip M Carpenter, Rita S Mehta, Darren Roblyer, Wei Yang, Keith D Paulsen, Brian Pogue, Shudong Jiang, Peter A Kaufman, So Hyun Chung, Mitchell Schnall, Bradley S Snyder, Nola Hylton, Stefan A Carp, Steven J Isakoff, David Mankoff, Bruce J Tromberg, Arjun G Yodh
Ideally, neoadjuvant chemotherapy (NAC) assessment should predict pathologic complete response (pCR), a surrogate clinical endpoint for 5-year survival, as early as possible during typical 3- to 6-month breast cancer treatments. We introduce and demonstrate an approach for predicting pCR within 10 days of initiating NAC. The method uses a bedside diffuse optical spectroscopic imaging (DOSI) technology and logistic regression modeling. Tumor and normal tissue physiological properties were measured longitudinally throughout the course of NAC in 33 patients enrolled in the American College of Radiology Imaging Network multicenter breast cancer DOSI trial (ACRIN-6691)...
October 2018: Journal of Biomedical Optics
https://www.readbyqxmd.com/read/30337080/fast-unsupervised-nuclear-segmentation-and-classification-scheme-for-automatic-allred-cancer-scoring-in-immunohistochemical-breast-tissue-images
#7
Aymen Mouelhi, Hana Rmili, Jaouher Ben Ali, Mounir Sayadi, Raoudha Doghri, Karima Mrad
BACKGROUND AND OBJECTIVE: This paper presents an improved scheme able to perform accurate segmentation and classification of cancer nuclei in immunohistochemical (IHC) breast tissue images in order to provide quantitative evaluation of estrogen or progesterone (ER/PR) receptor status that will assist pathologists in cancer diagnostic process. METHODS: The proposed segmentation method is based on adaptive local thresholding and an enhanced morphological procedure, which are applied to extract all stained nuclei regions and to split overlapping nuclei...
October 2018: Computer Methods and Programs in Biomedicine
https://www.readbyqxmd.com/read/30335537/seeing-what-works-identifying-and-enhancing-successful-interprofessional-collaboration-between-pathology-and-surgery
#8
Katherine Carroll, Jessica Mesman, Heidi McLeod, Judy Boughey, Gary Keeney, Elizabeth Habermann
Utilising frozen section technologies, Mayo Clinic has one of the lowest reoperation rates for breast lumpectomy in the United States. The research reported on sought to understand the successful teamwork between the Breast Surgery Team and the Frozen Section Laboratory at Mayo Clinic. Researchers worked collaboratively with healthcare staff from breast surgery and the frozen section pathology laboratory to identify communication styles and strategies that contribute to the timely and accurate intraoperative evaluation of breast cancer specimens...
October 18, 2018: Journal of Interprofessional Care
https://www.readbyqxmd.com/read/30335131/survival-analysis-of-carboplatin-added-to-an-anthracycline-taxane-based-neoadjuvant-chemotherapy-and-hrd-score-as-predictor-of-response-final-results-from-geparsixto
#9
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun, C T Salat, M Rezai, J U Blohmer, D M Zahm, C Jackisch, B Gerber, P Klare, S Kümmel, C Schem, S Paepke, R Schmutzler, K Rhiem, S Penn, J Reid, V Nekljudova, A-R Hartman, G von Minckwitz, M Untch
Background: In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). Patients and Methods: Patients were randomized to paclitaxel plus non-pegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb)...
October 18, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30334909/pharmacogenetic-variants-and-response-to-neoadjuvant-single-agent-doxorubicin-or-docetaxel-a-study-in-locally-advanced-breast-cancer-patients-participating-in-the-nct00123929-phase-2-randomized-trial
#10
Sara Ruiz-Pinto, Miguel Martin, Guillermo Pita, Daniela Caronia, Julio C de la Torre-Montero, Leticia T Moreno, Fernando Moreno, José Á García-Sáenz, Javier Benítez, Anna González-Neira
OBJECTIVES: Taxanes and anthracyclines are widely used in the treatment of breast cancer, although the benefit is limited to a proportion of patients and predictive biomarkers for clinical outcome remain elusive. PATIENTS AND METHODS: We carried out a pharmacogenetic study in 181 patients with locally advanced breast cancer enrolled in a phase 2 randomized clinical trial (NCT00123929), where patients were randomly assigned to receive neoadjuvant single-agent docetaxel 100 mg/m (n=84) or doxorubicin 75 mg/m (n=97)...
November 2018: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/30333003/decelerated-dna-methylation-age-predicts-poor-prognosis-of-breast-cancer
#11
Jun-Ting Ren, Mei-Xia Wang, Yi Su, Lu-Ying Tang, Ze-Fang Ren
BACKGROUND: DNA methylation (DNAm) age was found to be an indicator for all-cause mortality, cancer incidence, and longevity, but no study has involved in the associations of DNAm age with the prognosis of breast cancer. METHODS: We retrieved information of 1076 breast cancer patients from Genomic Data Commons (GDC) data portal on March 30, 2017, including breast cancer DNAm profiling, demographic features, clinicopathological parameters, recurrence, and all-cause fatality...
October 17, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30328048/multivariate-machine-learning-models-for-prediction-of-pathologic-response-to-neoadjuvant-therapy-in-breast-cancer-using-mri-features-a-study-using-an-independent-validation-set
#12
Elizabeth Hope Cain, Ashirbani Saha, Michael R Harowicz, Jeffrey R Marks, P Kelly Marcom, Maciej A Mazurowski
PURPOSE: To determine whether a multivariate machine learning-based model using computer-extracted features of pre-treatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer patients. METHODS: Institutional review board approval was obtained for this retrospective study of 288 breast cancer patients at our institution who received NAT and had a pre-treatment breast MRI...
October 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30327857/-ki67-biological-intertumor-variance-versus-variance-of-assay
#13
REVIEW
H Kreipe
Since its first description at the Institute of Pathology in Kiel more than 34 years ago, the immunohistochemical proliferation marker Ki67 has been shown to be of prognostic significance in a huge number of retrospective and even some prospective trials on malignant tumours of various tissue derivation. Lack of standardization in the evaluation provides potential sources of variance in assessment. Tumour area to be assessed, minimum number of cells to be analyzed, tedious counting cell by cell or semiquantitative eyeballing, choice of immunohistochemical techniques represent nonstandardized issues that potentially lead to considerable assay heterogeneity...
October 16, 2018: Der Pathologe
https://www.readbyqxmd.com/read/30327564/a-prediction-model-for-underestimation-of-invasive-breast-cancer-after-a-biopsy-diagnosis-of-ductal-carcinoma-in-situ-based-on-2892-biopsies-and-589-invasive-cancers
#14
Claudia J C Meurs, Joost van Rosmalen, Marian B E Menke-Pluijmers, Bert P M Ter Braak, Linda de Munck, Sabine Siesling, Pieter J Westenend
BACKGROUND: Patients with a biopsy diagnosis of ductal carcinoma in situ (DCIS) might be diagnosed with invasive breast cancer at excision, a phenomenon known as underestimation. Patients with DCIS are treated based on the risk of underestimation or progression to invasive cancer. The aim of our study was to expand the knowledge on underestimation and to develop a prediction model. METHODS: Population-based data were retrieved from the Dutch Pathology Registry and the Netherlands Cancer Registry for DCIS between January 2011 and June 2012...
October 17, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/30325755/circulating-tumor-cells-overview-and-opportunities-in-cytology
#15
Kaitlin E Sundling, Alarice C Lowe
Circulating tumor cells (CTCs) have long been assumed to be the substrate of cancer metastasis. However, only in recent years have we begun to leverage the potential of CTCs found in minimally invasive peripheral blood specimens to improve care for cancer patients. Currently, CTC enumeration is an accepted prognostic indicator for breast, prostate, and colorectal cancer; however, CTC enumeration remains largely a research tool. More recently, the focus has shifted to CTC characterization and isolation which holds great promise for predictive testing...
October 15, 2018: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/30325492/ophtalmoplegia-complicating-sino-orbital-mucormycosis
#16
Walid Zbiba, Emna Bouayed, Nadia Ben Abdesslem, Issam Elleuch, Malek Kharrat
PURPOSE: To report a case of complete ophthalmoplegia and blindness in sino-orbital mucormycosis. CASE REPORT: A 68-year-old woman with history of diabetes and breast cancer presented with sudden onset of fever, orbital pain and blindness in the right eye. The patient was found to have no light perception, complete ophthalmoplegia, chemosis, corneal ulcer and optic nerve atrophy. In rhinologic examination, necrosis was noticed. Brain and orbit magnetic resonance imaging showed diffuse sinusitis with orbital involvement...
March 2018: La Tunisie Médicale
https://www.readbyqxmd.com/read/30324492/systematic-analysis-of-parameters-predicting-pathological-axillary-status-ypn0-vs-ypn-in-patients-with-breast-cancer-converting-from-cn-to-ycn0-through-primary-systemic-therapy-pst
#17
C Liedtke, Hans-Christian Kolberg, L Kerschke, D Görlich, I Bauerfeind, T Fehm, B Fleige, G Helms, A Lebeau, A Stäbler, S Schmatloch, M Hausschild, L Schwentner, Gunter von Minckwitz, S Loibl, M Untch, T Kühn
Optimization of axillary staging among patients converting from clinically node-positive disease to clinically node-negative disease through primary systemic therapy is needed. We aimed at developing a nomogram predicting the probability of positive axillary status after chemotherapy based on clinical/pathological parameters. Patients from study arm C of the SENTINA trial were included. Univariable/multivariable analyses were performed for 13 clinical/pathological parameters to predict a positive pathological axillary status after chemotherapy using logistic regression models...
October 15, 2018: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/30324275/efficacy-of-neoadjuvant-pertuzumab-in-addition-to-chemotherapy-and-trastuzumab-in-routine-clinical-treatment-of-patients-with-primary-breast-cancer-a-multicentric-analysis
#18
Peter A Fasching, Andreas D Hartkopf, Paul Gass, Lothar Häberle, Leyla Akpolat-Basci, Alexander Hein, Bernhard Volz, Florin-Andrei Taran, Naiba Nabieva, Birgit Pott, Friedrich Overkamp, Hanna Einarson, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Wolfgang Janni, Tanja N Fehm, Andreas Schneeweiss, Michael Untch, Dirk Pott, Michael P Lux, Thomas Geyer, Cornelia Liedtke, Harald Seeger, Sarah Wetzig, Arndt Hartmann, Rüdiger Schulz-Wendtland, Erik Belleville, Diethelm Wallwiener, Matthias W Beckmann, Sara Y Brucker, Hans-Christian Kolberg
PURPOSE: Neoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM). This analysis was aimed at real-world validation of these results from prospective randomized trials. METHODS: In a retrospective analysis conducted in the PRAEGNANT network, patients were eligible for inclusion if they had either received neoadjuvant therapy with CTX/TZM or chemotherapy, trastuzumab, and pertuzumab (CTX/TZM/PTZ) and subsequently underwent surgery for their primary breast cancer...
October 15, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30324273/a-nomogram-to-predict-pathologic-complete-response-pcr-and-the-value-of-tumor-infiltrating-lymphocytes-tils-for-prediction-of-response-to-neoadjuvant-chemotherapy-nac-in-breast-cancer-patients
#19
REVIEW
Hye Won Hwang, Hera Jung, Jiyeon Hyeon, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong-Han Yu, Se Kyung Lee, Misun Choi, Soo Youn Cho, Eun Yoon Cho
PURPOSE: The value of tumor-infiltrating lymphocytes (TILs) for prediction of pathologic complete response (pCR) in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) has received increasing attention. In human epidermal growth factor receptor 2 (HER2)-positive BC, advances in HER2-targeted therapy have not yet clarified the clinical implications of pre-NAC TILs. Likewise, the prognostic role of TILs for long-term survival is not well established. METHODS: Pre- and post-NAC TIL levels were evaluated in 248 pair-matched pre-NAC biopsy and post-NAC resection samples, and analyzed for predictive and prognostic significance with other clinicopathologic parameters...
October 15, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30323666/locoregional-recurrence-associated-factors-and-risk-adapted-postmastectomy-radiotherapy-for-breast-cancer-staged-in-ct1-2n0-1-after-neoadjuvant-chemotherapy
#20
Xin Wang, Liming Xu, Zhenzhen Yin, Daquan Wang, Qi Wang, Kunpeng Xu, Jinlin Zhao, Lujun Zhao, Zhiyong Yuan, Ping Wang
Objective: In order to identify risk factors associated with locoregional recurrence (LRR) and assess the role of postmastectomy radiotherapy (PMRT) in early breast cancer (BC), managed with neoadjuvant chemotherapy (NAC) and mastectomy, a retrospective analysis of BC diagnosed with clinical stage T1-2N0-1 was conducted. Patients and methods: A total of 217 patients were included in this analysis. The median age was 50 years (24-72 years). The clinical stage distributions were cT1 in 15 cases, cT2 in 202, cN0 in 53, and cN1 in 161 cases...
2018: Cancer Management and Research
keyword
keyword
158315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"